citalopram + pioglitazone

Citalopram + pioglitazone is a combination of two small molecule drugs, each with distinct mechanisms of action. Citalopram is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat depression by inhibiting the sodium-dependent serotonin transporter, thereby increasing serotonergic neurotransmission in the brain[1]. Pioglitazone is a thiazolidinedione antidiabetic agent that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity and glycemic control in patients with type 2 diabetes[4][5]. This combination does not have an established fixed-dose product or unique brand name and is not commonly marketed together; however, both agents may be co-administered in clinical practice for comorbid conditions such as depression and diabetes. There are known pharmacokinetic interactions between these drugs when co-administered, but no specific combination product exists[2].